In our current study, we show that in actual clinical samples from CRC patients, human CRC tumor tissue has significant up-regulation of CDKN2A compared to corresponding unaffected colon tissue independent of histological staging, and this up-regulation is more marked in tumors with the KRAS mutation. This evidence concerns the gene CDKN2A and neoplasm.